Tumor cells often evade immune pressure via metabolic reprogramming, yet the key metabolic regulators orchestrating this process remain incompletely defined. Here, using in vivo me
Sound preclinical and ex vivo mechanistic work demonstrating a proof-of-concept approach to reduce placental IgG transport, with a functional disease model showing attenuation of fetal pathology, but requiring clinical translation.